Protein kinase C β inhibition: The promise for treatment of diabetic nephropathy

Current Opinion in Nephrology and Hypertension

Volumn 16, Issue 5, 2007, Pages 397-402

  Anderson, Pamela W ^a   McGill, Janet B ^b   Tuttle, Katherine R ^c  

^a ELI LILLY AND COMPANY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Diabetic nephropathy; Protein kinase C

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; B LYMPHOCYTE GROWTH FACTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; PLACEBO; PROTEIN KINASE C BETA; RUBOXISTAURIN;

ALBUMINURIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERANCE; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; INDOLES; MALEIMIDES; MODELS, CHEMICAL; PROTEIN KINASE C; TREATMENT OUTCOME;

EID: 34547922467     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3281ead025     Document Type: Review

References (38)

1. International Diabetes Federation. Diabetes atlas. 2nd ed. Brussels: International Diabetes Federation; 2003.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431.
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-1053.
4. Rowley W, Bezold C. Diabetes forecasts to 2025 and beyond: the looming crisis demands change. Alexandria, VA: Institute for Alternative Futures; 2005. http://www.altfutures.com/foresight/ IAF%20Diabetes%20Looming%20Crisis%20Forecasts%20Nov%202005.pdf. [Accessed 3 April 2007]
5. Tuttle KR, Nelson RG (editors), for the KDOQI Work Group. National Kidney Foundation - Kidney Disease Outcomes Quality Initiative (KDOQI), Clinical practice guidelines for diabetes and chronic kidney disease. Am J Kid Dis 2007; 49:S42-S61. The new National Kidney Foundation Kidney Disease Outcomes Quality Initiative offers comprehensive guidelines on chronic kidney disease and diabetes, emphasizing diabetes prevention, screening and management of kidney disease.
6. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.
7. United States Renal Data System. Annual data report: incidence and prevalence. Am J Kidney Dis 2007; 49:S67-S84.
8. Camamori ML, Kim Y, Huang C, et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional in patients with long-standing type 1 diabetes. Diabetes 2002; 51:506-513.
9. Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003; 14:1396-1405.
10. Chavers BM, Bilous RW, Ellis EN, et al. Glomerular lesions and urinary albumin excretion in type I diabetic patients without overt proteinuria. N Engl J Med 1989; 320:966-970.
11. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
13. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117.
14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.
15. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
16. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
17. Goekjian PG, Jirousek MR. Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors and agents in development. Curr Med Chem 1999; 6:877-903.
18. Ayo SH, Radnik R, Garoni JA, et al. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell culture. Am J Physiol 1991; 261:F571-F577.
19. Craven PA, Davidson CM, DeRubertis FR. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990; 39:667-674.
20. Craven PA, DeRubertis FR. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest 1989; 83:1667-1675.
21. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform β2 and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci U S A 1992; 89:11059-11063.
22. DeRubertis FR, Craven PA. Activation of protein kinase Cin glomerular cells in diabetes: mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 1994; 43:1-8.
23. Williams B, Schrier RW. Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J Clin Invest 1993; 92:2889-2896.
24. Jirousek MR, Gillig JR, Gonzalez CM, et al. (S)-13- [(dimethylamino)methyl]-10,11,14,15-tetrohydro-4,9:16,21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[ 3,4-h][1,4,13]-oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ. J Med Chem 1996; 39:2664-2671.
25. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996; 272:728-731.
26. Koya D, Jirousek MR, Lin YW, et al. Characterization of protein kinase C β isoform activation on the expression of transforming growth factor-β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997; 100:115-126.
27. Kelly DJ, Zhang Y, Hepper C, et al. Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003; 52:512-518.
28. Kelly DJ, Buck D, Zhang Y, Gilbert RE. Combination therapy with ruboxistaurin and perindopril is more renoprotective than monotherapy in the diabetic Ren-2 rat [abstract]. In: 18th European Diabetic Nephropathy Study Group (EDNSG), Arnhem, The Netherlands, 13-14 May 2005.
29. Koya D, Haneda M, Nakagawa H, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14:439-447.
30. 1 and connective tissue growth factor.
31. Meek RL, Cooney SK, Flynn SD, et al. Amino acids induce indicators of response to injury in glomerular mesangial cells. Am J Physiol 2003; 285:F79-F86.
32. Tuttle KR, Johnson EC, Cooney SK, et al. Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney Int 2005; 67:953-968.
33. Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28:2686-2690.
34. 1:creatinine ratio.
35. Tuttle KR, McGill JB, Haney DJ, et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. CJASN (in press).
36. The PKC-DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006; 113:2221-2230. In the largest ophthalmic trial of ruboxistaurin to date (n=685), diabetic patients with moderate to severe retinopathy were followed on ruboxistaurin 32 mg/day or placebo for 3 years. At the endpoint, sustained moderate visual loss had occurred in 9.1% of placebo-treated patients versus 5.5% of ruboxistaurin-treated patients (P=0.034, 40% risk reduction).
37. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54:2188-2197.
38. McGill JB, King GL, Berg PH, et al. Clinical safety of the selective PKC ß inhibitor, ruboxistaurin. Expert Opin Drug Saf 2006; 5:835-845. This publication describes the safety of ruboxistaurin in the first 11 placebo-controlled, randomized, double-blind, clinical trials completed as of 2006. Data from 2804 patients with diabetes (1396 taking ruboxistaurin 32 mg/day and 1408 taking placebo) were included. There was no significant difference between these two groups in the proportion of patients who died, reported one or more serious adverse events or discontinued from the study. First-degree atrioventricular block, superficial thrombosis, chalazion, posterior capsule opacification, dyspepsia, increased blood creatine phosphokinase, micturition urgency and skin discoloration were more common in the ruboxistaurin treatment group than in the placebo treatment group.